Bloomios

Bloomios EBIT Growth

The Year-over-Year EBIT Growth of Bloomios (BLMS) as of Nov 4, 2026 is -21.35 %. In the previous year, Year-over-Year EBIT Growth was -417.50 % — a change of -94.89% (higher).

EBIT Growth

-21.35 %

YoY

-94.89%

Last updated:

Year-over-Year EBIT Growth of Bloomios is 2023 -21.35 % . Year-over-Year EBIT Growth of Bloomios was 2022 -417.50 % . It decreases by -94.89% higher compared to the previous year.

The Bloomios EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2019
-4,564.34 USD
Jan 1, 2020
96.38 USD
Jan 1, 2021
-4,644.11 USD
Jan 1, 2022
-417.50 USD
Jan 1, 2023
-21.35 USD
The Bloomios EBIT Growth history
YEAREBIT GrowthYoY
-21.35 %-94.89%
-417.50 %-91.01%
-4,644.11 %-4,918.31%
96.38 %-102.11%
-4,564.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bloomios Stock analysis

What does Bloomios do? Bloomios, Inc. generates revenue through the wholesale distribution of U.S. hemp-derived supplements and cosmetic products. The company manufactures and distributes hemp-infused edibles, pet edibles, tinctures, shots, topicals, smokable hemp, and other products across seven categories including edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats. BPL, a subsidiary of Bloomios, focuses on manufacturing and distributing hemp-derived nootropic and nutraceutical products to wholesalers and retailers. Bloomios provides private-label and white-label services with over 80 customizable products and custom formulation and manufacturing support for its customers. The company's primary customers are wholesalers and retailers who purchase its hemp-derived products for resale. Bloomios offers a comprehensive suite of services including custom formulation, order fulfillment, and brand development to support its clients. Its product portfolio spans multiple categories such as human edibles, pet edibles, liquid consumables, topicals, and smokable hemp, catering to both consumer and pet markets. Bloomios leverages its subsidiary BPL to expand its product offerings in the hemp-derived nootropic and nutraceutical sectors. The company's focus on customizable solutions allows it to serve a diverse range of clients seeking private-label and white-label hemp products. Through its wholesale distribution channels, Bloomios targets businesses looking to sell hemp-based supplements and cosmetics under their own brand names. Bloomios is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bloomios stock

Year-over-Year EBIT Growth of Bloomios is -21.35 % in 2023.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Bloomios since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Bloomios historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Bloomios

All Key Metrics — Bloomios